The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic…
Psychiatric disorders such as anxiety, posttraumatic stress disorder (PTSD), and insomnia frequently coexist with major depressive disorder (MDD) and present treatment challenges to psychiatrists…
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be…
Glaucoma is a progressive disease of the optic nerve caused by high intraocular pressure (IOP); it is one of the leading causes of vision loss in Europe. Treatment of glaucoma aims to lower and…
The prevalence of HBV is a major public health concern in China. Patients chronically infected with HBV are at high risk of developing hepatic cirrhosis and hepatocellular carcinoma. The majority…
The chronic obstructive pulmonary disease (COPD) market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics will…
Copy/Paste the key inputs from the product brochure, per guidance from Marketing. The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: tumor…
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) have been gaining traction in the chronic obstructive pulmonary disease (COPD) therapy…
Copy/Paste the key inputs from the product brochure, per guidance from Marketing. The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy…
Migraine is a neurological condition characterized by moderate to severe headaches of variable frequency that can be highly disabling and lower quality of life. Although triptans have long…
Bispecific therapies represent a class of drug with two binding sites directed at two different antigens or epitopes. This dual action makes bispecific therapies a promising approach to improve…
In 2021, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $130 billion in the major pharmaceutical markets under study (United…
In 2021, sales of branded biologics in immunology exceeded $70 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…
In 2021, sales of branded biologics for respiratory indications reached nearly $0.7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2021-2031…